Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Curr Infect Dis Rep. 2007 Jan;9(1):39-46.

Prevention and treatment of vivax malaria.

Author information

  • 1ALERTAsia Foundation, c/o Eijkman Institute for Molecular Biology, Jalan Diponegoro No. 69, Menteng, Jakarta 10430, Indonesia. kbaird@alertasia.org


Plasmodium vivax is a significant public health threat throughout most of the tropics and to travelers to these regions. The infection causes a debilitating febrile syndrome that often recurs and in rare cases ends in death. The complex life cycle of the parasite compounds the difficulty of prevention and treatment, principally due to the phenomenon of relapse. Most commonly used drugs for preventing malaria fail to prevent late relapses by this parasite. Treatment requires dealing with both blood and liver stages. Since 1950, primaquine has been the only drug available for treatment of liver stages, and important clinical questions surround its appropriate use (ie, dosing, efficacy, safety, and tolerability). Likewise, chloroquine has been first-line therapy for vivax malaria since 1946, and the emergence of resistance to the drug further complicates therapeutic management decisions.

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk